Consequences of the Metabolic Syndrome

Chapter

Various recent studies have described the association among the metabolic syndrome, diabetes, and cardiovascular disease (CVD) morbidity and mortality (including all-cause mortality where applicable). The findings may vary with the diagnostic criteria used. The relative risk of the metabolic syndrome was generally highest for coronary heart disease (CHD) mortality, intermediate for CVD mortality, and lowest (and not necessarily statistically significant) for all-cause mortality [1]. Because the prevalence of the metabolic syndrome is increasing alarmingly among adolescents and young adults, it is important to quantify its relation with clinical coronary artery disease (CAD) occurring early in life.

Keywords

Insulin Resistance Coronary Heart Disease Metabolic Syndrome Obstructive Sleep Apnea Coronary Heart Disease Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Byrne CD, Wild SH. The Metabolism Syndrome. New York: John Wiley & Sons, 2005.CrossRefGoogle Scholar
  2. 2.
    Lakka H-M, Laaksonen DE, Lakha TA, et al. The metabolic syndrome and total and CVD mortality in middle-aged men. JAMA 2002;288:2709–2716.CrossRefPubMedGoogle Scholar
  3. 3.
    Hunt KJ, Resendez WK, Haffner SM, et al. NCEP vs. WHO metabolic in relation to all-cause and CV mortality in the San Antonio Heart Study. Circulation 2004;110:1251–1257.CrossRefPubMedGoogle Scholar
  4. 4.
    Grundy SM. Metabolic syndrome: connecting and reconciling CV and diabetes world. J Am Coll Cardiol 2006;47:1093–1100.CrossRefPubMedGoogle Scholar
  5. 5.
    Li TY, Rana JS, Manson JE, et al. Obesity as compared with physical activity in predicting risk of CHD in women. Circulation 2006;113:499–506.CrossRefPubMedGoogle Scholar
  6. 6.
    Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003;26(11):3153–3159.CrossRefPubMedGoogle Scholar
  7. 7.
    Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality for CHD, CVD, and all causes in US. Circulation 2004;110:1245–1250.CrossRefPubMedGoogle Scholar
  8. 8.
    Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of CVD in type 2 diabetes subjects. Prospective data. Diabet Med 2004;21:52.CrossRefPubMedGoogle Scholar
  9. 9.
    Ninomiya JK, L’Italien G, Crighi MH, et al. Association of metabolic syndrome with history of myocardial infarction and stroke in the 3rd NHANES survey. Circulation 2004;109:42–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Palter MK, Meigs JB, Sullivan LM, et al. CRP, the metabolic syndrome and prediction of CV events in the Framingham Offspring Study. Circulation 2004;110:380–385.CrossRefGoogle Scholar
  11. 11.
    Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and CVD mortality in non-diabetic European men and women. Arch Intern Med 2004;164:1066–1076.CrossRefPubMedGoogle Scholar
  12. 12.
    Lakka HM, Lakka TA, Tuomilehto J, et al. Abdominal obesity is associated with increased risk of coronary events in men. Eur Heart J 2002;23:706.CrossRefPubMedGoogle Scholar
  13. 13.
    Hsia J, Bitter V, Tripputi M, et al. Metabolic syndrome and coronary angiographic disease progression: the Women’s Angiographic Vitamin and Estrogen Trial. Am Heart J 2003;146:439–445.CrossRefPubMedGoogle Scholar
  14. 14.
    Ridker PM, Buring JE, Cook NR, et al. CRP, the metabolic syndrome, and risk of incident CV events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391–397.CrossRefPubMedGoogle Scholar
  15. 15.
    Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes and prevalence of CHD among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–1214.CrossRefPubMedGoogle Scholar
  16. 16.
    Guzder RN, Gatling W, Mulleo MA, et al. Impact of metabolic syndrome criteria on CVD risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006;49:49–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Iribarren C, Go AS, Husson G, et al. Metabolic syndrome and earlyonset CAD. Is the whole greater than its parts. J Am Coll Cardiol 2006;48(9):1800–1807.CrossRefPubMedGoogle Scholar
  18. 18.
    Wilson P, D’Agostino R, Parise H, et al. Metabolic syndrome as a precursor of CVD and type 2 diabetes. Circulation 2005;112:3066–3072.CrossRefPubMedGoogle Scholar
  19. 19.
    Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident CVD events and death. J Am Coll Cardiol 2007;49:403–414.CrossRefPubMedGoogle Scholar
  20. 20.
    Ninomiya JK, L’Halien G, Crigui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third NHANES survey. Circulation 2004;109:42–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997;100:1166–1173.CrossRefPubMedGoogle Scholar
  22. 22.
    Ford ES, Mukdad AH, Giles WH. Trends in waist circumference among US adults. Obes Res 2003;11:1223–1231.CrossRefPubMedGoogle Scholar
  23. 23.
    Gordon T, Castelli WP, Hjortland MC, et al. HDL as a protective factor against CHD. The Framingham Study. Am J Med 1977;62:707–714.CrossRefPubMedGoogle Scholar
  24. 24.
    Relationship between baseline risk factors and CHD and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986;15:254–273.Google Scholar
  25. 25.
    Assman G, Schulte H. Role of triglycerides in CVD: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992;70:10H–13H.CrossRefGoogle Scholar
  26. 26.
    Hopkins PN, Wu LL, Hunt SC, et al. Plasma triglycerides and type II hyperlipidemia are independently associated with premature familial CAD. J Am Coll Cardiol 2005;45:1003–1012.CrossRefPubMedGoogle Scholar
  27. 27.
    Klein BE, Klein R, Lee KE. Components of metabolic syndrome and risk of CVD and diabetes in Beaver Dam. Diabetes Care 2002;25:1790–1794.CrossRefPubMedGoogle Scholar
  28. 28.
    Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of CVD. J Clin Endocrinol Metab 1998;83:2773–2776.CrossRefPubMedGoogle Scholar
  29. 29.
    Lamarche B, St. Pierre AC, Rue IL, et al. A prospective populationbased study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 2001;17:859–865.PubMedGoogle Scholar
  30. 30.
    Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, LDL particle size diameter, and risk of myocardial infarction. JAMA 1996;276:882–888.CrossRefPubMedGoogle Scholar
  31. 31.
    Freedman DS, Otvus JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to CAD. Arterioscler Thromb Vasc Biol 1998;18:1046–1053.PubMedGoogle Scholar
  32. 32.
    Walldius G, Juugner I, Holme I, et al. High ApoB B, low apoB A-I, and improvement in the prediction of fatal myocardial infarction: a prospective study. Lancet 2001;358:2026–2033.CrossRefPubMedGoogle Scholar
  33. 33.
    Havel RJ. Role of triglyceride-rich lipoprotein in progression of atherosclerosis. Circulation 1990;81:694–696.PubMedGoogle Scholar
  34. 34.
    Hodis HN, Mack WJ, Azeu SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a different effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42–49.PubMedGoogle Scholar
  35. 35.
    Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apoB, CIII, E, and risk of recurrent CV in the CARE trial. Circulation 2000;102:1886–1892.PubMedGoogle Scholar
  36. 36.
    Schaefer EJ, McNamaro JR, Shah PK, et al. Elevated RLPs-cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002;25:989–994.CrossRefPubMedGoogle Scholar
  37. 37.
    Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005;333:326–335.CrossRefGoogle Scholar
  38. 38.
    Day CP. NASH: Where are we now and where are we going? Gut 2002;50:585–588.CrossRefPubMedGoogle Scholar
  39. 39.
    Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of NAFLD with insulin resistance. Am J Med 1999;107(5):450–455.CrossRefPubMedGoogle Scholar
  40. 40.
    Neuschwander-Teri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007;23:193–198.CrossRefGoogle Scholar
  41. 41.
    Leclercq IA. Antioxidant defense mechanism: new players in the pathogenesis of non-alcoholic steatohepatitis. Clin Sci (Lond) 2004;106(3):235–237.CrossRefGoogle Scholar
  42. 42.
    Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004;106(3):261–268.CrossRefGoogle Scholar
  43. 43.
    Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 2003;112(1):91–100.PubMedGoogle Scholar
  44. 44.
    Shimomura I, Bashmakov Y, Horton JD, et al. Increased level of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999;274(42):30028–30032.CrossRefPubMedGoogle Scholar
  45. 45.
    Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167–1174.PubMedGoogle Scholar
  46. 46.
    Neuschwander-Teri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003;38(4):1008–1017.Google Scholar
  47. 47.
    Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39(1): 188–196.CrossRefPubMedGoogle Scholar
  48. 48.
    Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfraction in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001;54:447–453.CrossRefGoogle Scholar
  49. 49.
    Kelly CJ, Lyall H, Petrie JR, et al. A specific elevation in tissue plasminogen activator antigen in women with PCOS. J Clin Endocrinol Metab 2002;87:3287–3290.CrossRefPubMedGoogle Scholar
  50. 50.
    Escobar-Morreale HF, Botella-Carretero JI, Villuendal G, et al. Serum IL-18 concentrations are increased in the PCOS: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004;89:806–811.CrossRefPubMedGoogle Scholar
  51. 51.
    Horborne L, Fleming R, Lyall H, et al. Descriptive reviews of the evidence for the use of metformin in PCOS. Lancet 2003;361:1894–1901.CrossRefGoogle Scholar
  52. 52.
    Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed PCOS. Metabolism 2003;52:908–915.CrossRefPubMedGoogle Scholar
  53. 53.
    Belli SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with PCOS. Fertil Steril 2004;81:624–629.CrossRefPubMedGoogle Scholar
  54. 54.
    Jayagopal V, Kilpatrick ES, Holding S, et al. Orlistat beneficial as metformin in the treatment of PCOS. J Clin Endocrinol Metab 2004;90:729–733.CrossRefPubMedGoogle Scholar
  55. 55.
    Coughlin SR, Mawdsley L, Mugarza JA. Obstruction sleep apnea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004;25:735–741.CrossRefPubMedGoogle Scholar
  56. 56.
    Gami AS, Somers VK. OSA and metabolic syndrome and CV outcome. Eur Heart J 2004;25:709–711.CrossRefPubMedGoogle Scholar
  57. 57.
    Teramoto S, Yamamoto H, Yamaguchi Y, et al. OSA causes systemic inflammation and metabolic syndrome. Chest 2005;127:1074–1075.CrossRefPubMedGoogle Scholar
  58. 58.
    Alexandros N, Vgoutzas, Dimitris A, et al. Sleep apnea and day time sleepiness and fatigue. J Clin Endocrinol Metab 200;85:1151–1158.Google Scholar
  59. 59.
    Wolk R, Somers VK. Sleep apnea and hypertension. Exp Physiol 2007;92:67–68.CrossRefPubMedGoogle Scholar
  60. 60.
    Meigs JB, Wilson PW, Nathan DM et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio and Framingham Offspring Studies. Diabetes 2003;52:2160–2167.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2008

Personalised recommendations